Synthesis and evaluation of heteroaryl-ketone derivatives as a novel class of VEGFR-2 inhibitors

被引：10

作者：

Chekler, Eugene L. Piatnitski ^{[1
]}

Katoch-Rouse, Reeti ^{[1
]}

Kiselyov, Alexander S. ^{[1
]}

Sherman, Dan ^{[1
]}

Ouyang, Xiaohu ^{[1
]}

Kim, Ki ^{[1
]}

Wang, Ying ^{[2
]}

Hadari, Yaron R. ^{[2
]}

Doody, Jacqueline F. ^{[2
]}

机构：

[1] ImClone Syst Inc, Dept Chem, New York, NY 10014 USA

[2] ImClone Syst Inc, Dept Prot Sci, New York, NY 10014 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 15期

关键词：

angiogenesis; kinase inhibitor; vascular endothelial growth factor;

D O I：

10.1016/j.bmcl.2008.06.083

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We have discovered novel inhibitors of VEGFR-2 kinase with low nanomolar potency in both enzymatic and cell-based assays. Active series are heteroaryl-ketone compounds containing a central aromatic ring with either an indazolyl or indolyl keto group in the ortho orientation to the benzylic amine group (Fig. 1). The best compounds were demonstrated to be inactive against a small select panel of tyrosine and serine/threonine kinases with the exception of VEGFR-1 kinase, a close family member. In addition, the lead candidate 8 displayed acceptable exposure levels when administered orally to mice. (c) 2008 Elsevier Ltd. All rights reserved.

引用

页码：4344 / 4347

页数：4

共 21 条

[1]

[Anonymous], 1988, DEV BIOL

[2] Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].

Carmeliet, P ;

Ferreira, V ;

Breier, G ;

Pollefeyt, S ;

Kieckens, L ;

Gertsenstein, M ;

Fahrig, M ;

Vandenhoeck, A ;

Harpal, K ;

Eberhardt, C ;

Declercq, C ;

Pawling, J ;

Moons, L ;

Collen, D ;

Risau, W ;

Nagy, A .

NATURE, 1996, 380 (6573) :435-439

[3] Angiogenesis in health and disease [J].

Carmeliet, P .

NATURE MEDICINE, 2003, 9 (06) :653-660

[4] Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2 [J].

Eichmann, A ;

Corbel, C ;

Nataf, V ;

Vaigot, P ;

Breant, C ;

LeDouarin, NM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (10) :5141-5146

[5] Angiogenesis inhibitors in clinical development; where are we now and where are we going? [J].

Eskens, FALM .

BRITISH JOURNAL OF CANCER, 2004, 90 (01) :1-7

[6] The biology of VEGF and its receptors [J].

Ferrara, N ;

Gerber, HP ;

LeCouter, J .

NATURE MEDICINE, 2003, 9 (06) :669-676

[7] Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J].

Ferrara, N ;

CarverMoore, K ;

Chen, H ;

Dowd, M ;

Lu, L ;

OShea, KS ;

PowellBraxton, L ;

Hillan, KJ ;

Moore, MW .

NATURE, 1996, 380 (6573) :439-442

[8] ANGIOGENIC FACTORS [J].

FOLKMAN, J ;

KLAGSBRUN, M .

SCIENCE, 1987, 235 (4787) :442-447

[9] WHAT IS THE EVIDENCE THAT TUMORS ARE ANGIOGENESIS DEPENDENT [J].

FOLKMAN, J .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (01) :4-6

[10]

Hamilton W.J., 1962, HUMAN EMBRYOLOGY

← 1 2 3 →